The prostate cancer risk variant rs55958994 regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression.
Yuyang QianLei ZhangMingyang CaiHongxia LiHeming XuHongzhen YangZhongfang ZhaoSuhn Kyong RhiePeggy J FarnhamJiandang ShiWange LuPublished in: Science advances (2019)
Genome-wide association studies identified single-nucleotide polymorphism (SNP) rs55958994 as a significant variant associated with increased susceptibility to prostate cancer. However, the mechanisms by which this SNP mediates increased risk to cancer are still unknown. In this study, we show that this variant is located in an enhancer active in prostate cancer cells. Deletion of this enhancer from prostate tumor cells resulted in decreased tumor initiation, tumor growth, and invasive migration, as well as a loss of stem-like cells. Using a combination of capture chromosome conformation capture (Capture-C) and RNA sequencing, we identified genes on the same and different chromosomes as targets regulated by the enhancer. Furthermore, we show that expression of individual candidate target genes in an enhancer-deleted cell line rescued different aspects of tumorigenesis. Our data suggest that the rs55958994-associated enhancer affects prostate cancer progression by influencing expression of multiple genes via long-range chromatin interactions.
Keyphrases
- prostate cancer
- genome wide
- binding protein
- transcription factor
- gene expression
- dna methylation
- poor prognosis
- radical prostatectomy
- genome wide identification
- copy number
- genome wide association
- dna damage
- bioinformatics analysis
- single cell
- long non coding rna
- squamous cell carcinoma
- climate change
- artificial intelligence
- molecular dynamics simulations
- oxidative stress
- benign prostatic hyperplasia
- young adults